{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR3+Gene+Mutation",
    "query": {
      "condition": "FGFR3 Gene Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR3+Gene+Mutation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:10:57.663Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02706691",
      "title": "BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FGFR Gene Amplification",
        "FGFR1 Gene Amplification",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Mutation",
        "FGFR3 Gene Mutation",
        "Head and Neck Squamous Cell Carcinoma",
        "Human Papillomavirus Infection",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Nasopharynx Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "BGJ398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-06-01",
      "completion_date": "2019-02-11",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02706691"
    },
    {
      "nct_id": "NCT05544552",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Solid Tumor",
        "Urothelial Carcinoma",
        "Solid Tumor, Adult",
        "Bladder Cancer",
        "Non-muscle-invasive Bladder Cancer",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Alteration",
        "Advanced Solid Tumor",
        "Advanced Urothelial Carcinoma",
        "Urinary Tract Cancer",
        "Urinary Tract Tumor",
        "Urinary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2022-11-22",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worchester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544552"
    },
    {
      "nct_id": "NCT01752920",
      "title": "Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Derazantinib low dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib middle dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib high dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib at recommended phase 2 dose (RP2D)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2012-12-10",
      "completion_date": "2018-08-28",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01752920"
    },
    {
      "nct_id": "NCT00106977",
      "title": "Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Craniosynostosis",
        "Muenke Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 137,
      "start_date": "2005-03-31",
      "completion_date": "2020-03-23",
      "has_results": false,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00106977"
    },
    {
      "nct_id": "NCT02965378",
      "title": "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "FGFR1 Gene Amplification",
        "FGFR1 Gene Mutation",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Mutation",
        "FGFR3 Gene Amplification",
        "FGFR3 Gene Mutation",
        "Recurrent Squamous Cell Lung Carcinoma",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "FGFR Inhibitor AZD4547",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-10",
      "completion_date": "2019-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 1083,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02965378"
    },
    {
      "nct_id": "NCT02272998",
      "title": "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "ponatinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sameek Roychowdhury",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2015-02-24",
      "completion_date": "2022-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272998"
    },
    {
      "nct_id": "NCT07265947",
      "title": "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Upper Tract Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dabogratinib (TYRA-300) 60mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) 80mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2025-12-22",
      "completion_date": "2030-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 5,
      "location_summary": "Lisle, Illinois • Jeffersonville, Indiana • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Lisle",
          "state": "Illinois"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07265947"
    },
    {
      "nct_id": "NCT06995677",
      "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low-grade NMIBC",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "FGFR3 Gene Alteration",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Fusions"
      ],
      "interventions": [
        {
          "name": "TYRA-300 60mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 50mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 Dose TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-06-27",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 28,
      "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06995677"
    },
    {
      "nct_id": "NCT01004224",
      "title": "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3",
        "Squamous Lung Cancer With FGFR1 Amplification",
        "Bladder Cancer With FGFR3 Mutation or Fusion",
        "Advanced Solid Tumors With FGFR1 Amplication",
        "Advanced Solid Tumors With FGFR2 Amplication",
        "Advanced Solid Tumors With FGFR3 Mutation"
      ],
      "interventions": [
        {
          "name": "BGJ398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2009-12-11",
      "completion_date": "2018-10-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01004224"
    },
    {
      "nct_id": "NCT06915753",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Hepatocellular Carcinoma",
        "Solid Tumors",
        "Solid Tumor, Adult",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "FGFR3 Gene Alteration",
        "FGFR3 Gene Mutation",
        "Advanced Solid Tumors",
        "FGFR4 Gene Mutation",
        "FGFR4 Gene Fusions",
        "FGF19 Gene Amplification",
        "FGF19 Gene Overexpression",
        "FGFR3 Gene Fusions",
        "Locally Advanced Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-430",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-04-24",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-05-22T02:10:57.663Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06915753"
    }
  ]
}